Search

Your search keyword '"Goodfellow, Paul"' showing total 33 results

Search Constraints

Start Over You searched for: Author "Goodfellow, Paul" Remove constraint Author: "Goodfellow, Paul" Publisher academic press Remove constraint Publisher: academic press
33 results on '"Goodfellow, Paul"'

Search Results

1. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

2. FGFR2 mutations are rare across histologic subtypes of ovarian cancer

3. The contemporary presentation and diagnosis of endometrial cancer recurrence: When, where, and how?

4. Implementing universal upfront multi-gene panel testing in endometrial cancer: From cost to practical considerations.

5. Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients.

6. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.

8. Endometrial cancer: Molecular markers and management of advanced stage disease.

9. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

11. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.

12. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

13. Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer.

14. The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study.

15. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

16. Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor.

17. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

18. Hypermethylation of miR-203 in endometrial carcinomas.

19. Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables.

20. Frequent mutations in the RPL22 gene and its clinical and functional implications.

21. Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial cancer: a conserved regulatory mechanism important in tumorigenesis?

22. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer.

23. Infrequent methylation of the DUSP6 phosphatase in endometrial cancer.

24. Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas.

25. FGFR2 mutations are rare across histologic subtypes of ovarian cancer.

27. Absence of MGMT promoter methylation in endometrial cancer.

28. Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair.

29. Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility.

30. Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer.

31. Defective DNA mismatch repair and XRCC2 mutation in uterine carcinosarcomas.

32. IGSF4 promoter methylation and expression silencing in human cervical cancer.

33. Antisense transcripts at the EMX2 locus in human and mouse.

Catalog

Books, media, physical & digital resources